• head_banner_01

Renewable Design for Ligandrol - Ganirelix Acetate Peptide API – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

"Sincerity, Innovation, Rigorousness, and Efficiency" could be the persistent conception of our enterprise to the long-term to produce together with clients for mutual reciprocity and mutual profit for Calais, 1 2-Dimethyl-1h-Imidazole, Cetilistat, Our group members are goal to provides merchandise with significant performance cost ratio to our consumers, as well as target for all of us is usually to satisfy our consumers from all around the environment.
Renewable Design for Ligandrol - Ganirelix Acetate Peptide API – Gentolex Detail:

Product Detail

Name  Ganirelix Acetate
CAS number  123246-29-7
Molecular formula  C80H113ClN18O13
Molecular weight  1570.34

Synonyms

Ac-DNal-DCpa-DPal-Ser-Tyr-DHar(Et2)-Leu-Har(Et2)-Pro-DAla -NH2;Ganirelixum;ganirelix Acetate; GANIRELIX; Ganirelix Acetate USP/EP/

Description

Ganirelix is a synthetic decapeptide compound, and its acetate salt, Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. The amino acid sequence is: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-Tyr-D-HomoArg(9,10-Et2)-Leu-L-HomoArg(9,10-Et2)-Pro-D- Ala-NH2. Mainly clinically, it is used in women undergoing assisted reproductive technology controlled ovarian stimulation programs to prevent premature luteinizing hormone peaks and to treat fertility disorders due to this cause. The drug has the characteristics of less adverse reactions, high pregnancy rate and short treatment period, and has obvious advantages compared with similar drugs in clinical practice.

Pharmacological Action

The pulsatile release of gonadotropin-releasing hormone (GnRH) stimulates the synthesis and secretion of LH and FSH. The frequency of LH pulses in the mid and late follicular phases is approximately 1 per hour. These pulses are reflected in transient rises in serum LH. During mid-menstrual period, the massive release of GnRH causes a surge of LH. The midmenstrual LH surge can trigger several physiological responses, including: ovulation, oocyte meiotic resumption, and corpus luteum formation. The formation of the corpus luteum causes serum progesterone levels to rise, while estradiol levels fall. Ganirelix acetate is a GnRH antagonist that competitively blocks GnRH receptors on pituitary gonadotrophs and subsequent transduction pathways. It produces a rapid, reversible inhibition of gonadotropin secretion. The inhibitory effect of ganirelix acetate on pituitary LH secretion was stronger than that on FSH. Ganirelix acetate failed to induce the first release of endogenous gonadotropins, consistent with antagonism. Complete recovery of pituitary LH and FSH levels occurred within 48 hours after ganirelix acetate was discontinued.


Product detail pictures:

Renewable Design for Ligandrol - Ganirelix Acetate Peptide API – Gentolex detail pictures

Renewable Design for Ligandrol - Ganirelix Acetate Peptide API – Gentolex detail pictures


Related Product Guide:

We usually perform being a tangible workforce making sure that we will give you the most beneficial excellent plus the finest selling price for Renewable Design for Ligandrol - Ganirelix Acetate Peptide API – Gentolex , The product will supply to all over the world, such as: Kuwait, Sri Lanka, Iraq, To meet the requirements of specific customers for each bit more perfect service and stable quality merchandise. We warmly welcome customers around the world to visit us, with our multi-faceted cooperation, and jointly develop new markets, create a brilliant future!
  • It is not easy to find such a professional and responsible provider in today's time. Hope that we can maintain long-term cooperation.
    5 Stars By Madeline from Pakistan - 2017.11.12 12:31
    The customer service staff is very patient and has a positive and progressive attitude to our interest, so that we can have a comprehensive understanding of the product and finally we reached an agreement, thanks!
    5 Stars By Debby from Azerbaijan - 2017.09.22 11:32
    Write your message here and send it to us